{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:37:52Z","timestamp":1790815072996,"version":"4.1.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T00:00:00Z","timestamp":1766361600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"vor","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Japanese Society for the Promotion of Science Kakenhi Grant","award":["20K08278"],"award-info":[{"award-number":["20K08278"]}]},{"DOI":"10.13039\/501100008886","name":"Princess Takamatsu Cancer Research Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008886","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-32222-4","type":"journal-article","created":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T10:04:00Z","timestamp":1766397840000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Blockade of CC chemokine receptor 2 suppresses pancreatic cancer progression through the interaction with macrophages in the tumor microenvironment"],"prefix":"10.1038","volume":"15","author":[{"given":"Gen","family":"Kimura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Ijichi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Sano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genso","family":"Notoya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Miyabayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryota","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Kishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuhiro","family":"Fujishiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,22]]},"reference":[{"key":"32222_CR1","unstructured":"Foundation for Promotion of Cancer Research: CANCER STATISTICS IN JAPAN. (2021). https:\/\/ganjoho.jp\/public\/qa_links\/report\/statistics\/2021_jp.html)"},{"key":"32222_CR2","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S0140-6736(16)00141-0","volume":"388","author":"T Kamisawa","year":"2016","unstructured":"Kamisawa, T., Wood, L. D., Itoi, T. & Takaori, K. Pancreatic cancer. Lancet 388, 73\u201385. https:\/\/doi.org\/10.1016\/S0140-6736(16)00141-0 (2016).","journal-title":"Lancet"},{"key":"32222_CR3","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1001\/jama.2021.13027","volume":"326","author":"W Park","year":"2021","unstructured":"Park, W., Chawla, A. & O\u2019Reilly, E. M. Pancreatic cancer: A review. JAMA 326, 851\u2013862. https:\/\/doi.org\/10.1001\/jama.2021.13027 (2021).","journal-title":"JAMA"},{"key":"32222_CR4","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1053\/j.gastro.2018.12.039","volume":"156","author":"LD Wood","year":"2019","unstructured":"Wood, L. D., Yurgelun, M. B. & Goggins, M. G. Genetics of Familial and sporadic pancreatic cancer. Gastroenterology 156, 2041\u20132055. https:\/\/doi.org\/10.1053\/j.gastro.2018.12.039 (2019).","journal-title":"Gastroenterology"},{"key":"32222_CR5","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1159\/000123838","volume":"8","author":"JB Koorstra","year":"2008","unstructured":"Koorstra, J. B., Hustinx, S. R., Offerhaus, G. J. & Maitra, A. Pancreatic carcinogenesis. Pancreatology 8, 110\u2013125. https:\/\/doi.org\/10.1159\/000123838 (2008).","journal-title":"Pancreatology"},{"key":"32222_CR6","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1038\/s41401-020-00584-2","volume":"42","author":"HF Hu","year":"2021","unstructured":"Hu, H. F. et al. Mutations in key driver genes of pancreatic cancer: molecularly targeted therapies and other clinical implications. Acta Pharmacol. Sin. 42, 1725\u20131741. https:\/\/doi.org\/10.1038\/s41401-020-00584-2 (2021).","journal-title":"Acta Pharmacol. Sin"},{"key":"32222_CR7","doi-asserted-by":"publisher","first-page":"3147","DOI":"10.1101\/gad.1475506","volume":"20","author":"H Ijichi","year":"2006","unstructured":"Ijichi, H. et al. Aggressive pancreatic ductal adenocarcinoma in mice caused by pancreas-specific Blockade of transforming growth factor-beta signaling in Cooperation with active Kras expression. Genes Dev. 20, 3147\u20133160. https:\/\/doi.org\/10.1101\/gad.1475506 (2006).","journal-title":"Genes Dev."},{"key":"32222_CR8","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/s41571-020-0363-5","volume":"17","author":"WJ Ho","year":"2020","unstructured":"Ho, W. J., Jaffee, E. M. & Zheng, L. The tumour microenvironment in pancreatic cancer - clinical challenges and opportunities. Nat. Rev. Clin. Oncol. 17, 527\u2013540. https:\/\/doi.org\/10.1038\/s41571-020-0363-5 (2020).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"32222_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13122860","author":"A. R. Poh","year":"2021","unstructured":"Poh, A. R. & Ernst, M. Tumor-Associated macrophages in pancreatic ductal adenocarcinoma: therapeutic opportunities and clinical challenges. Cancers (Basel) (2021). https:\/\/doi.org\/10.3390\/cancers13122860 (2021).","journal-title":"Cancers (Basel)"},{"key":"32222_CR10","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/nri3073","volume":"11","author":"PJ Murray","year":"2011","unstructured":"Murray, P. J. & Wynn, T. A. Protective and pathogenic functions of macrophage subsets. Nat. Rev. Immunol. 11, 723\u2013737. https:\/\/doi.org\/10.1038\/nri3073 (2011).","journal-title":"Nat. Rev. Immunol."},{"key":"32222_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21155291","author":"S. van Clemente","year":"2020","unstructured":"Clemente, S., van Waarde, G., Antunes, A. F., D\u00f6mling, I. & Elsinga, H. & A. & Arginase as a potential biomarker of disease progression: A molecular imaging perspective. Int. J. Mol. Sci. (2020). https:\/\/doi.org\/10.3390\/ijms21155291 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"32222_CR12","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.immuni.2014.06.010","volume":"41","author":"R Noy","year":"2014","unstructured":"Noy, R. & Pollard, J. W. Tumor-associated macrophages: from mechanisms to therapy. Immunity 41, 49\u201361 (2014).","journal-title":"Immunity"},{"key":"32222_CR13","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s13046-016-0412-1","volume":"35","author":"L Kong","year":"2016","unstructured":"Kong, L. et al. Deletion of interleukin-6 in monocytes\/macrophages suppresses the initiation of hepatocellular carcinoma in mice. J. Exp. Clin. Cancer Res. 35, 131. https:\/\/doi.org\/10.1186\/s13046-016-0412-1 (2016).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"32222_CR14","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1073\/pnas.1612920114","volume":"114","author":"V Prima","year":"2017","unstructured":"Prima, V., Kaliberova, L. N., Kaliberov, S., Curiel, D. T. & Kusmartsev, S. COX2\/mPGES1\/PGE2 pathway regulates PD-L1 expression in tumor-associated macrophages and myeloid-derived suppressor cells. Proc. Natl. Acad. Sci. U S A. 114, 1117\u20131122. https:\/\/doi.org\/10.1073\/pnas.1612920114 (2017).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"32222_CR15","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41417-021-00303-x","volume":"29","author":"K Kohli","year":"2022","unstructured":"Kohli, K., Pillarisetty, V. G. & Kim, T. S. Key chemokines direct migration of immune cells in solid tumors. Cancer Gene Ther. 29, 10\u201321. https:\/\/doi.org\/10.1038\/s41417-021-00303-x (2022).","journal-title":"Cancer Gene Ther."},{"key":"32222_CR16","doi-asserted-by":"publisher","first-page":"4106","DOI":"10.1172\/JCI42754","volume":"121","author":"H Ijichi","year":"2011","unstructured":"Ijichi, H. et al. Inhibiting Cxcr2 disrupts tumor-stromal interactions and improves survival in a mouse model of pancreatic ductal adenocarcinoma. J. Clin. Invest. 121, 4106\u20134117. https:\/\/doi.org\/10.1172\/JCI42754 (2011).","journal-title":"J. Clin. Invest."},{"key":"32222_CR17","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41389-018-0117-8","volume":"8","author":"M Sano","year":"2019","unstructured":"Sano, M. et al. Blocking CXCLs-CXCR2 axis in tumor-stromal interactions contributes to survival in a mouse model of pancreatic ductal adenocarcinoma through reduced cell invasion\/migration and a shift of immune-inflammatory microenvironment. Oncogenesis 8, 8. https:\/\/doi.org\/10.1038\/s41389-018-0117-8 (2019).","journal-title":"Oncogenesis"},{"key":"32222_CR18","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/j.ccell.2016.04.014","volume":"29","author":"CW Steele","year":"2016","unstructured":"Steele, C. W. et al. CXCR2 Inhibition profoundly suppresses metastases and augments immunotherapy in pancreatic ductal adenocarcinoma. Cancer Cell. 29, 832\u2013845. https:\/\/doi.org\/10.1016\/j.ccell.2016.04.014 (2016).","journal-title":"Cancer Cell."},{"key":"32222_CR19","doi-asserted-by":"publisher","first-page":"28697","DOI":"10.18632\/oncotarget.7376","volume":"7","author":"SY Lim","year":"2016","unstructured":"Lim, S. Y., Yuzhalin, A. E., Gordon-Weeks, A. N. & Muschel, R. J. Targeting the CCL2-CCR2 signaling axis in cancer metastasis. Oncotarget 7, 28697\u201328710. https:\/\/doi.org\/10.18632\/oncotarget.7376 (2016).","journal-title":"Oncotarget"},{"key":"32222_CR20","doi-asserted-by":"publisher","unstructured":"Grossman, J. G. et al. Recruitment of CCR2. Oncoimmunology 7, e1470729, (2018). https:\/\/doi.org\/10.1080\/2162402X.2018.1470729","DOI":"10.1080\/2162402X.2018.1470729"},{"key":"32222_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22168530","author":"S. Kadomoto","year":"2021","unstructured":"Kadomoto, S., Izumi, K. & Mizokami, A. Roles of CCL2-CCR2 axis in the tumor microenvironment. Int. J. Mol. Sci. (2021). https:\/\/doi.org\/10.3390\/ijms22168530 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"32222_CR22","doi-asserted-by":"publisher","first-page":"e13115","DOI":"10.1111\/cpr.13115","volume":"54","author":"M Xu","year":"2021","unstructured":"Xu, M., Wang, Y., Xia, R., Wei, Y. & Wei, X. Role of the CCL2-CCR2 signalling axis in cancer: mechanisms and therapeutic targeting. Cell. Prolif. 54, e13115. https:\/\/doi.org\/10.1111\/cpr.13115 (2021).","journal-title":"Cell. Prolif."},{"key":"32222_CR23","doi-asserted-by":"publisher","first-page":"3404","DOI":"10.1158\/1078-0432.CCR-13-0525","volume":"19","author":"DE Sanford","year":"2013","unstructured":"Sanford, D. E. et al. Inflammatory monocyte mobilization decreases patient survival in pancreatic cancer: a role for targeting the CCL2\/CCR2 axis. Clin. Cancer Res. 19, 3404\u20133415. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-0525 (2013).","journal-title":"Clin. Cancer Res."},{"key":"32222_CR24","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1158\/0008-5472.CAN-11-1792","volume":"72","author":"AM Lesokhin","year":"2012","unstructured":"Lesokhin, A. M. et al. Monocytic CCR2(+) myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment. Cancer Res. 72, 876\u2013886. https:\/\/doi.org\/10.1158\/0008-5472.CAN-11-1792 (2012).","journal-title":"Cancer Res."},{"key":"32222_CR25","doi-asserted-by":"publisher","first-page":"122","DOI":"10.4049\/jimmunol.180.1.122","volume":"180","author":"HW Lim","year":"2008","unstructured":"Lim, H. W., Lee, J., Hillsamer, P. & Kim, C. H. Human Th17 cells share major trafficking receptors with both polarized effector T cells and FOXP3\u2009+\u2009regulatory T cells. J. Immunol. 180, 122\u2013129. https:\/\/doi.org\/10.4049\/jimmunol.180.1.122 (2008).","journal-title":"J. Immunol."},{"key":"32222_CR26","doi-asserted-by":"publisher","first-page":"4697","DOI":"10.4049\/jimmunol.166.7.4697","volume":"166","author":"M Mack","year":"2001","unstructured":"Mack, M. et al. Expression and characterization of the chemokine receptors CCR2 and CCR5 in mice. J. Immunol. 166, 4697\u20134704. https:\/\/doi.org\/10.4049\/jimmunol.166.7.4697 (2001).","journal-title":"J. Immunol."},{"key":"32222_CR27","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. U S A. 102, 15545\u201315550. https:\/\/doi.org\/10.1073\/pnas.0506580102 (2005).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"32222_CR28","doi-asserted-by":"publisher","first-page":"e102994","DOI":"10.1371\/journal.pone.0102994","volume":"9","author":"N Jetten","year":"2014","unstructured":"Jetten, N. et al. Wound administration of M2-polarized macrophages does not improve murine cutaneous healing responses. PLoS One. 9, e102994. https:\/\/doi.org\/10.1371\/journal.pone.0102994 (2014).","journal-title":"PLoS One"},{"key":"32222_CR29","doi-asserted-by":"publisher","first-page":"52294","DOI":"10.18632\/oncotarget.10561","volume":"7","author":"F Zhang","year":"2016","unstructured":"Zhang, F. et al. TGF-\u03b2 induces M2-like macrophage polarization via SNAIL-mediated suppression of a pro-inflammatory phenotype. Oncotarget 7, 52294\u201352306. https:\/\/doi.org\/10.18632\/oncotarget.10561 (2016).","journal-title":"Oncotarget"},{"key":"32222_CR30","doi-asserted-by":"publisher","first-page":"1160719","DOI":"10.3389\/fimmu.2023.1160719","volume":"14","author":"T Xia","year":"2023","unstructured":"Xia, T. et al. Advances in the role of STAT3 in macrophage polarization. Front. Immunol. 14, 1160719. https:\/\/doi.org\/10.3389\/fimmu.2023.1160719 (2023).","journal-title":"Front. Immunol."},{"key":"32222_CR31","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1002\/kjm2.12222","volume":"36","author":"H Xiao","year":"2020","unstructured":"Xiao, H. et al. Knockout of E2F1 enhances the polarization of M2 phenotype macrophages to accelerate the wound healing process. Kaohsiung J. Med. Sci. 36, 692\u2013698. https:\/\/doi.org\/10.1002\/kjm2.12222 (2020).","journal-title":"Kaohsiung J. Med. Sci."},{"key":"32222_CR32","doi-asserted-by":"publisher","first-page":"48436","DOI":"10.18632\/oncotarget.17061","volume":"8","author":"X Zheng","year":"2017","unstructured":"Zheng, X. et al. Redirecting tumor-associated macrophages to become tumoricidal effectors as a novel strategy for cancer therapy. Oncotarget 8, 48436\u201348452. https:\/\/doi.org\/10.18632\/oncotarget.17061 (2017).","journal-title":"Oncotarget"},{"key":"32222_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13051037","author":"S. E. Fenton","year":"2021","unstructured":"Fenton, S. E., Saleiro, D. & Platanias, L. C. Type I and II interferons in the Anti-Tumor immune response. Cancers (Basel) (2021). https:\/\/doi.org\/10.3390\/cancers13051037 (2021).","journal-title":"Cancers (Basel)"},{"key":"32222_CR34","doi-asserted-by":"publisher","first-page":"105","DOI":"10.4049\/jimmunol.1800598","volume":"202","author":"DW Williams","year":"2019","unstructured":"Williams, D. W., Askew, L. C., Jones, E. & Clements, J. E. CCR2 signaling selectively regulates IFN-\u03b1: role of \u03b2-Arrestin 2 in IFNAR1 internalization. J. Immunol. 202, 105\u2013118. https:\/\/doi.org\/10.4049\/jimmunol.1800598 (2019).","journal-title":"J. Immunol."},{"key":"32222_CR35","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/S1470-2045(16)00078-4","volume":"17","author":"TM Nywening","year":"2016","unstructured":"Nywening, T. M. et al. Targeting tumour-associated macrophages with CCR2 Inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial. Lancet Oncol. 17, 651\u2013662. https:\/\/doi.org\/10.1016\/S1470-2045(16)00078-4 (2016).","journal-title":"Lancet Oncol."},{"key":"32222_CR36","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1136\/gutjnl-2017-313738","volume":"67","author":"TM Nywening","year":"2018","unstructured":"Nywening, T. M. et al. Targeting both tumour-associated CXCR2+ neutrophils and CCR2+ macrophages disrupts myeloid recruitment and improves chemotherapeutic responses in pancreatic ductal adenocarcinoma. Gut 67, 1112\u20131123. https:\/\/doi.org\/10.1136\/gutjnl-2017-313738 (2018).","journal-title":"Gut"},{"key":"32222_CR37","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1158\/1078-0432.CCR-19-1868","volume":"26","author":"IG House","year":"2020","unstructured":"House, I. G. et al. Macrophage-Derived CXCL9 and CXCL10 are required for antitumor immune responses following immune checkpoint Blockade. Clin. Cancer Res. 26, 487\u2013504. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-1868 (2020).","journal-title":"Clin. Cancer Res."},{"key":"32222_CR38","doi-asserted-by":"publisher","first-page":"8219","DOI":"10.1128\/JVI.78.15.8219-8228.2004","volume":"78","author":"V van Pesch","year":"2004","unstructured":"van Pesch, V., Lanaya, H., Renauld, J. C. & Michiels, T. Characterization of the murine alpha interferon gene family. J. Virol. 78, 8219\u20138228. https:\/\/doi.org\/10.1128\/JVI.78.15.8219-8228.2004 (2004).","journal-title":"J. Virol."},{"key":"32222_CR39","doi-asserted-by":"publisher","first-page":"e1314424","DOI":"10.1080\/2162402X.2017.1314424","volume":"6","author":"M Musella","year":"2017","unstructured":"Musella, M., Manic, G., De Maria, R., Vitale, I. & Sistigu, A. Type-I-interferons in infection and cancer: unanticipated dynamics with therapeutic implications. Oncoimmunology 6, e1314424. https:\/\/doi.org\/10.1080\/2162402X.2017.1314424 (2017).","journal-title":"Oncoimmunology"},{"key":"32222_CR40","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1038\/sj.onc.1205179","volume":"21","author":"L Thyrell","year":"2002","unstructured":"Thyrell, L. et al. Mechanisms of Interferon-alpha induced apoptosis in malignant cells. Oncogene 21, 1251\u20131262. https:\/\/doi.org\/10.1038\/sj.onc.1205179 (2002).","journal-title":"Oncogene"},{"key":"32222_CR41","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.3748\/wjg.v11.i10.1521","volume":"11","author":"JH Ma","year":"2005","unstructured":"Ma, J. H. et al. Synergistic effects of interferon-alpha in combination with chemoradiation on human pancreatic adenocarcinoma. World J. Gastroenterol. 11, 1521\u20131528. https:\/\/doi.org\/10.3748\/wjg.v11.i10.1521 (2005).","journal-title":"World J. Gastroenterol."},{"key":"32222_CR42","doi-asserted-by":"publisher","first-page":"322","DOI":"10.3389\/fonc.2018.00322","volume":"8","author":"M Budhwani","year":"2018","unstructured":"Budhwani, M., Mazzieri, R. & Dolcetti, R. Plasticity of type I Interferon-Mediated responses in cancer therapy: from Anti-tumor immunity to Resist1ance. Front. Oncol. 8, 322. https:\/\/doi.org\/10.3389\/fonc.2018.00322 (2018).","journal-title":"Front. Oncol."},{"key":"32222_CR43","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/s41573-018-0011-2","volume":"18","author":"EC Borden","year":"2019","unstructured":"Borden, E. C. Interferons \u03b1 and \u03b2 in cancer: therapeutic opportunities from new insights. Nat. Rev. Drug Discov. 18, 219\u2013234. https:\/\/doi.org\/10.1038\/s41573-018-0011-2 (2019).","journal-title":"Nat. Rev. Drug Discov"},{"key":"32222_CR44","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s00018-022-04219-z","volume":"79","author":"R Yu","year":"2022","unstructured":"Yu, R., Zhu, B. & Chen, D. Type I interferon-mediated tumor immunity and its role in immunotherapy. Cell. Mol. Life Sci. 79, 191. https:\/\/doi.org\/10.1007\/s00018-022-04219-z (2022).","journal-title":"Cell. Mol. Life Sci."},{"key":"32222_CR45","doi-asserted-by":"publisher","DOI":"10.1172\/JCI143296","author":"M. Von Locquenghien","year":"2021","unstructured":"Von Locquenghien, M., Rozal\u00e9n, C. & Celi\u00e0-Terrassa, T. Interferons in cancer immunoediting: sculpting metastasis and immunotherapy response. J. Clin. Invest. (2021). https:\/\/doi.org\/10.1172\/JCI143296 (2021).","journal-title":"J. Clin. Invest."},{"key":"32222_CR46","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s13058-019-1140-1","volume":"21","author":"OK Provance","year":"2019","unstructured":"Provance, O. K. & Lewis-Wambi, J. Deciphering the role of interferon alpha signaling and microenvironment crosstalk in inflammatory breast cancer. Breast Cancer Res. 21, 59. https:\/\/doi.org\/10.1186\/s13058-019-1140-1 (2019).","journal-title":"Breast Cancer Res."},{"key":"32222_CR47","doi-asserted-by":"publisher","first-page":"103204","DOI":"10.1016\/j.critrevonc.2020.103204","volume":"159","author":"A Blaauboer","year":"2021","unstructured":"Blaauboer, A., Sideras, K., van Eijck, C. H. J. & Hofland, L. J. Type I interferons in pancreatic cancer and development of new therapeutic approaches. Crit. Rev. Oncol. Hematol. 159, 103204. https:\/\/doi.org\/10.1016\/j.critrevonc.2020.103204 (2021).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"32222_CR48","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1038\/ng.3398","volume":"47","author":"RA Moffitt","year":"2015","unstructured":"Moffitt, R. A. et al. Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. Nat. Genet. 47, 1168\u20131178. https:\/\/doi.org\/10.1038\/ng.3398 (2015).","journal-title":"Nat. Genet."},{"key":"32222_CR49","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nature16965","volume":"531","author":"P Bailey","year":"2016","unstructured":"Bailey, P. et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature 531, 47\u201352. https:\/\/doi.org\/10.1038\/nature16965 (2016).","journal-title":"Nature"},{"key":"32222_CR50","doi-asserted-by":"publisher","first-page":"e83381","DOI":"10.7554\/eLife.53381","volume":"9","author":"TD Somerville","year":"2020","unstructured":"Somerville, T. D. et al. Squamous trans-differentiation of pancreatic cancer cells promotes stromal inflammation. eLife 9, e83381. https:\/\/doi.org\/10.7554\/eLife.53381 (2020).","journal-title":"eLife"},{"key":"32222_CR51","doi-asserted-by":"publisher","unstructured":"Weischenfeldt, J. & Porse, B. Bone Marrow-Derived Macrophages (BMM): Isolation and Applications. CSH Protoc Dec 1:2008:pdb.prot5080, (2008). https:\/\/doi.org\/10.1101\/pdb.prot5080 (2008).","DOI":"10.1101\/pdb.prot5080"},{"key":"32222_CR52","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/cas.12080","volume":"104","author":"R Takahashi","year":"2013","unstructured":"Takahashi, R. et al. Therapeutic effect of c-Jun N-terminal kinase Inhibition on pancreatic cancer. Cancer Sci. 104, 337\u2013344. https:\/\/doi.org\/10.1111\/cas.12080 (2013).","journal-title":"Cancer Sci."},{"key":"32222_CR53","doi-asserted-by":"publisher","first-page":"btz854","DOI":"10.1093\/bioinformatics\/btz854","volume":"15","author":"C Prieto","year":"2019","unstructured":"Prieto, C., Barrios, D. & RaNA-Seq Interactive RNA-Seq analysis from FASTQ files to functional analysis. Bioinformatics Nov. 15, btz854. https:\/\/doi.org\/10.1093\/bioinformatics\/btz854 (2019).","journal-title":"Bioinformatics Nov"},{"key":"32222_CR54","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1038\/s41467-019-09234-6","volume":"10","author":"Y Zhou","year":"2019","unstructured":"Zhou, Y. et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat. Commun. 10, 1523. https:\/\/doi.org\/10.1038\/s41467-019-09234-6 (2019).","journal-title":"Nat. Commun."},{"key":"32222_CR55","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1172\/JCI29919","volume":"117","author":"C-L Tsou","year":"2007","unstructured":"Tsou, C-L. et al. Critical roles for CCR2 and MCP-3 in monocyte mobilization from bone marrow and recruitment to inflammatory sites. J. Clin. Invest. 117, 902\u2013909. https:\/\/doi.org\/10.1172\/JCI29919 (2007).","journal-title":"J. Clin. Invest."},{"key":"32222_CR56","doi-asserted-by":"publisher","first-page":"3232","DOI":"10.1038\/onc.2016.483","volume":"36","author":"M Amit","year":"2017","unstructured":"Amit, M. et al. Upregulation of RET induces perineurial invasion of pancreatic adenocarcinoma. Oncogene 36, 3232\u20133239. https:\/\/doi.org\/10.1038\/onc.2016.483 (2017).","journal-title":"Oncogene"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-32222-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-32222-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-32222-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T17:05:25Z","timestamp":1777395925000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-32222-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,22]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["32222"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-32222-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,22]]},"assertion":[{"value":"21 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors have declared that no conflict of interest exists.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"45078"}}